Skip to main content

Change location

You are currently on the Denmark (English) website

My country is not on the list

Global

  • Bracco.com (English)

Asia

  • China (中文)
  • Japan (日本語)
  • South Korea (한국어)

Americas

  • Brazil (Português)
  • Canada (English)
  • Mexico (English)
  • Canada (Français)
  • USA (English)

Europe

  • Austria (English)
  • Belgium (English)
  • Czech Republic (English)
  • Denmark (English)
  • Finland (English)
  • France (Français)
  • Germany (Deutsch)
  • Iceland (English)
  • Italy (Italiano)
  • Luxembourg (English)
  • Norway (English)
  • Poland (English)
  • Slovakia (English)
  • Sweden (English)
  • Switzerland (English)
  • The Netherlands (English)
  • UK (English)
  • Careers
  • Media and News
  • Get in touch
    • Denmark (English)
  • Home
  • we are bracco
    We are Bracco

    Welcome to a World of contrasts

    • Our businesses
    • Purpose and values
    • Our history
    • Our Foundation
    • Responsibility and Ethical conduct
  • Our portfolio

    Proven offerings for a proven difference

    • X-Ray & CT
      • Contrast agents

        • Iomeron
      • Medical devices

        • CT Exprès
        • Protoco2l Touch
        • Empower CTA+
    • MRI
      • Contrast agents

        • Vueway (Gadopiclenol)
        • MultiHance
        • ProHance
      • Medical Devices

        • Empower MR
    • Ultrasound
      • Contrast agents

        • Sonovue
      • Software

        • VueBox
    • Nuclear
      • Radiopharmaceutical

        • CardioGen-82
    • Interventional Cardiology
      • Contrast agents

        • Iomeron
      • Medical devices

        • ACIST CVi
        • ACIST HDi
        • ACIST RXi
    • Digital solutions
    • Oncology
    • Cardiology
  • Woman looking into microscope
    Innovation

    A deep dive into our R&D progress

    • Digital future
    • R&D
    • The Bracco sites
    • Scientific heritage and patents
  • knowledge
    Knowledge

    Current activities and future opportunities

    • E-learning
    • Partnerships in education
    • Events
  • Child walking next to plants and touching their leaves
    Sustainability

    Our game plan and goals for a better world

    • Our sustainability pillars
    • Governance and transparency
    • Sustainability report
  • Our stories
  1. Home
  2. Our portfolio
  3. Nuclear
  4. Radiopharmaceutical

  5. CardioGen-82

CardioGen82_Logo_Registered_RGB

Cardiogen-82 3.3-5.6 GBq radionuclide generator. 


Please refer to the Summary of Product Characteristics (SmPC) before prescribing.

Denmark - Cardiogen-82 SPC 12/18/2024 pdf Download
 
 
Abbreviated Prescribing Information
  • Cardiogen-82 is a radionuclide generator of rubidium-82 (Rb-82) containing strontium-82 (Sr-82) adsorbed on stannic oxide in a chromatography column. It provides a means of obtaining, via elution, a sterile, non-pyrogenic injectable solution of rubidium-82 (Rb-82) chloride. The activity of the generator is between 3.3 and 5.6 gigabecquerel (GBq) Sr-82 at calibration time. The activity of the rubidium-82 (Rb-82) chloride solution obtained from each elution depends on the elution capacity of the generator. The specifications can be found in the SmPC. On each use, when eluted at a rate of no more than 50 mL/minute, each generator eluate should contain no more than 1x10-5 megabecquerel (MBq) of strontium-82 (Sr-82) and no more than 1x10-4 MBq of strontium-85 (Sr-85) per MBq of injectable solution of rubidium-82 (Rb-82) chloride. 1 mL of solution contains 9 mg of sodium chloride.

  • This medicinal product is for diagnostic use only. The generator eluate (solution of rubidium-82 (Rb-82) chloride for injection) is used for Positron Emission Tomography (PET) imaging of the myocardium at rest or under pharmacologic stress conditions to evaluate regional myocardial perfusion in adults with suspected or known coronary artery disease.

  • Rubidium-82 (Rb-82) chloride solution for injection is intended only for intravenous administration. Recommended adult and elderly dose: 1100 to 2220 MBq (adjusted according to patient’s body size, PET equipment used, and imaging technique employed) by intravenous infusion. Cardiogen-82 should be used with an appropriate infusion system designed specifically for use with the Cardiogen-82 generator, e.g., Cardiogen-82 Infusion System Model 510 or Model 1701. Refer to the SmPC for product preparation instructions before administration. This radiopharmaceutical should be administered at a rate of 50 mL/minute (Model 510 or Model 1701) or 20 mL/minute (Model 1701 only) through a catheter inserted into a large peripheral vein, with the maximum volume per infusion of 100 mL, and a total volume not exceeding 200 mL. The elution rate should never exceed 50 mL/minute, as this could lead to breakthrough of strontium-82 (Sr-82). Image acquisition: In general, two doses should be administered in order to carry out both a rest imaging and a pharmacological stress imaging session. See SmPC for full details.

  • Pregnancy. Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of SmPC.

  • No undesirable effects associated with Cardiogen-82 were observed during clinical studies. The application of vasodilator pharmacologic stress may cause serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, broncho-constriction, and cerebrovascular events. Perform testing only in settings where cardiac resuscitation equipment and trained staff are readily available.

  • If hypersensitivity or anaphylactic reactions occur, the administration of the medicinal product must be discontinued immediately and intravenous treatment initiated, if necessary. To enable immediate action in emergencies, the necessary medicinal products, personnel and equipment such as endotracheal tube and ventilator must be immediately available.

     

    For each patient, the ionising radiation exposure must be justifiable by the likely benefit. The activity administered should in every case be as low as reasonably achievable to obtain the required diagnostic information.

     

    Unintended patient exposure to ionising radiation due to contamination with strontium can occur in patients receiving rubidium-82 (Rb-82) chloride from the Cardiogen-82 generator at clinical sites where quality control is not carried out correctly. Strict adherence to the instructions regarding quality control at clinical sites is required. The eluate must not be used if the specified generator eluate limits have been exceeded.

     

    High level radiation exposure to the bone marrow has occurred in some patients due to strontium-82 (Sr-82) and/or strontium-85 (Sr-85) breakthrough in the eluate when an incorrect solution was used to elute the Cardiogen-82 generator. Use only pharmacopeial grade additive-free NaCl 9 mg/mL solution to elute the generator.

     

    Heart failure patients: Rubidium-82 (Rb-82) chloride solution contains sodium. According to the time of injection, the content of sodium administered may in some cases be greater than 1 mmol. This should be taken into account in patients on strict low sodium diets. Patients with congestive heart failure should be monitored particularly carefully during infusion because of the transitory nature increase in blood volume.

     

    Patient preparation: Patient should fast for at least 6 hours and should be well hydrated, before the start
    of the examination. In addition, the patient should not consume food products that contain caffeine and/
    or other xanthine derivatives (e.g., coffee, tea, chocolate, cola and other soft drinks, maté, guarana) for at least 12 hours before the examination. The intake of medicinal products which could affect the results of the pharmacologic stress imaging should be avoided/stopped at least one day before the start of the examination based on the opinion of the attending nuclear physician/expert and the indication of the examination.

  • In order to avoid administration of a large quantity of strontium-82 (Sr-82) and/or strontium-85 (Sr-85) (breakthrough), the instructions for use should be strictly adhered to and the maximum elution rate should not exceed 50 mL/minute.

     

    Consult the SmPC for further information relating to adverse reactions, warnings and precautions.

  • Denmark 68262

The Model 1701 Infusion System is focused on efficiency, safety and ease of use

 

 

  • Efficient cardiac PET myocardial perfusion imaging (MPI) offers diagnostic confidence
     
  • Intelligent software maintains quality standards
     
  • Convenient for patients and clinicians
     
  • Enhances patient management in a busy imaging department
Cardiogen-82 and the Model 1701 Infusion System. 05/09/2023 pdf Download

PROFESSIONAL SERVICES

 

The Professional Services Group is available to assist health care professionals with requests for scientific or medical information about Bracco Imaging products.

 

[email protected]

Contact us


Please fill out the form below and we will get back to you.

Different countries may have specific processes in place to handle reports of adverse reactions. To report an adverse reaction related to Bracco products, you can find specific contacts and information selecting the page "Pharmacovigilance" of your country.

I have read and I agree with the Bracco Privacy Policy

* I have read the BraccoHealthCare Professionals Privacy Notice and I consent to the processing of my personal data allowing Bracco Imaging SpA (Data Controller) to conduct its business or scientific operations and contact me with promotional communication through email, SMS, and other digital and offline channels, such as mobile apps and social media.

Please login to DocCheck
to view our products

Register here Forgot your password?

The Bracco Group is an international group of highly specialized companies.
We are an active part of the healthcare sector, and a global leader in diagnostic imaging.

  • We are Bracco
  • Our portfolio
  • Innovation
  • Knowledge
  • Sustainability
  • Our stories
  • Pharmacovigilance
  • Data Protection

Connect with us

Via Egidio Folli 50
20134 Milan, Italy
Phone + 39 02 2177.1

  • Terms of Use
  • Privacy Policy
  • Cookie Policy
  • Imprint
  • for Bracco VPN users

Bracco Copyright © 2025 | Registered office: Via E. Folli, 50, 20134 Milano, Italy | Share Capital € 104.000.000 f.p. | VAT Milan Comp. Reg. n. 00825120157 | Milan REA n. 348182